Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Bill Passes; Congress Adds $225 Million To Industry User Fee Burden

Executive Summary

Final FDA reform legislation that cleared Congress adds an additional $225 million to industry's user fee tab over five years, but limits penalties that FDA can assess to enforce its new authorities to mandate labeling changes and postmarket studies

You may also be interested in...



FDA Working To Fill Advisory Panel Vacancies While Tightening Conflict-Of-Interest Rules

FDA is working on an initiative to fill many of the current vacancies on its advisory committees, but it is not backing down from a strict conflict-of-interest policy that many see as contributing to the advisory panel vacancies

FDA Working To Fill Advisory Panel Vacancies While Tightening Conflict-Of-Interest Rules

FDA is working on an initiative to fill many of the current vacancies on its advisory committees, but it is not backing down from a strict conflict-of-interest policy that many see as contributing to the advisory panel vacancies

FDA Working To Fill Advisory Panel Vacancies While Tightening Conflict-Of-Interest Rules

FDA's revised draft guidance adds requirement for public disclosure of the company or institution that is the source of a conflict.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS048817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel